Treatment of the heparin-induced thrombosisthrombocytopenia syndrome by very low dose streptokinase Emile Ferrari, Philippe Morand, Marcel Baudouy Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin treatment.' 2 The onset of thrombosis in this context raises a very difficult therapeutic problem because 29% mortality and a 21% limb amputation rate are reported when this complication occurs.3 Oral anticoagulant treatment does not always prevent complications, which may occur before the oral anticoagulant becomes effective. In addition to stopping heparin treatment and starting treatment with oral anticoagulant, interruption of the vena cava, thrombectomy, and antiplatelet agents have all been tried, with a low success rate. We describe a patient with HIT in whom extensive venous thrombosis was treated very effectively with low-dose thrombolysis.
A 71 year old woman was admitted to hospital for investigation of arrhythmia. Endocavitary exploration required a lengthy procedure (more than 3 hours) and involved many venous routes of access, the right femoral in particular. She was treated with subcutaneous heparin for the five days after this investigation. Three HIT is a serious complication of heparin treatment. In our patient, HIT was complicated by extensive venous thrombosis of both legs and a threatening clot above the renal veins. The treatment strategy was intended to limit the thrombogenic effects of HIT while the oral anticoagulants became fully effective. The increase in D-dimers, disappearance of soluble complexes, and the increase in platelet count indicated that the thrombolytic treatment was effective.
Thrombolytic treatment while dissolving clots may have prevented platelet consumption and have impeded the process of heparininduced thrombocytopenia.
Thrombotic complications secondary to immuno-allergic heparin-induced thrombocytopenia are relatively common because of the widespread use of heparin. An effective treatment is vital because the mortality and morbidity are high in patients with this syndrome. Few cases of thrombolytic treatment of HIT have been described.46 In all of them a fulldose thrombolytic treatment was used. The risk of bleeding associated with these full doses must be weighed against the potential benefit of lysis of thromboses, and this is bound to limit the use of such a treatment. In our case small doses of streptokinase were totally effective. Perhaps, as our case seems to show, the platelet-fibrin composition of thrombi in this syndrome is amenable to a lower thrombolytic dose regimen. Bearing in mind the very poor prognosis of HIT with extensive thrombosis, its iatrogenic cause, and the lack of an effective treatment, thrombolysis is certainly worth evaluating. I low dose streptokinase. 
